<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="centre remains active. Abstract An outbreak related to the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in"/>
 <result pre="remains active. Abstract An outbreak related to the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan,"/>
 <result pre="active. Abstract An outbreak related to the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China"/>
 <result pre="An extremely high potential for dissemination resulted in the global" exact="coronavirus disease" post="2019 (COVID-19) pandemic in 2020. Despite the worsening trends"/>
 <result pre="extremely high potential for dissemination resulted in the global coronavirus" exact="disease" post="2019 (COVID-19) pandemic in 2020. Despite the worsening trends"/>
 <result pre="potency in vitro. The roles of teicoplanin (which inhibits the" exact="viral" post="genome exposure in cytoplasm) and monoclonal and polyclonal antibodies"/>
 <result pre="non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or angiotensin II" exact="type I" post="receptor blockers is advised for COVID-19 patients. Keywords Severe"/>
 <result pre="type I receptor blockers is advised for COVID-19 patients. Keywords" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019"/>
 <result pre="I receptor blockers is advised for COVID-19 patients. Keywords Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19)"/>
 <result pre="receptor blockers is advised for COVID-19 patients. Keywords Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) Remdesivir"/>
 <result pre="blockers is advised for COVID-19 patients. Keywords Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) Coronavirus disease 2019 (COVID-19) Remdesivir Hydroxychloroquine"/>
 <result pre="COVID-19 patients. Keywords Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="Coronavirus disease" post="2019 (COVID-19) Remdesivir Hydroxychloroquine Non-steroidal anti-inflammatory drugs Angiotensin converting"/>
 <result pre="patients. Keywords Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus" exact="disease" post="2019 (COVID-19) Remdesivir Hydroxychloroquine Non-steroidal anti-inflammatory drugs Angiotensin converting"/>
 <result pre="found to be caused by a novel virus, the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2).1, 2, 3 Numerous clinical"/>
 <result pre="to be caused by a novel virus, the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2).1, 2, 3 Numerous clinical SARS-Co-2"/>
 <result pre="be caused by a novel virus, the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2).1, 2, 3 Numerous clinical SARS-Co-2 cases"/>
 <result pre="period (data till March 28, 2020).4, 5, 6, 7 The" exact="lower" post="respiratory tract is the primary target of the SARS-CoV-2"/>
 <result pre="(data till March 28, 2020).4, 5, 6, 7 The lower" exact="respiratory" post="tract is the primary target of the SARS-CoV-2 infection."/>
 <result pre="2020).4, 5, 6, 7 The lower respiratory tract is the" exact="primary" post="target of the SARS-CoV-2 infection. It is noteworthy that"/>
 <result pre="of the SARS-CoV-2 infection. It is noteworthy that adults with" exact="coronavirus disease" post="2019 (COVID-19) often present with a profound decrease in"/>
 <result pre="the SARS-CoV-2 infection. It is noteworthy that adults with coronavirus" exact="disease" post="2019 (COVID-19) often present with a profound decrease in"/>
 <result pre="at the early stage of this disease.1,8 Subsequently, patients suffered" exact="acute respiratory distress syndrome" post="for about 7–10 days after the onset of COVID-19"/>
 <result pre="the early stage of this disease.1,8 Subsequently, patients suffered acute" exact="respiratory" post="distress syndrome for about 7–10 days after the onset"/>
 <result pre="stage of this disease.1,8 Subsequently, patients suffered acute respiratory distress" exact="syndrome" post="for about 7–10 days after the onset of COVID-19"/>
 <result pre="7–10 days after the onset of COVID-19 due to rapid" exact="viral" post="replication, a stormy increase of pro-inflammatory cytokines as well"/>
 <result pre="Nevertheless, contrary to the SARS cases in 2003,10 some SARS-CoV-2" exact="infection" post="patients did not have the prodromal symptoms of upper"/>
 <result pre="SARS-CoV-2 infection patients did not have the prodromal symptoms of" exact="upper respiratory tract infection" post="(e.g., cough, sore throat, rhinorrhea), viremia-associated laboratory abnormalities (e.g.,"/>
 <result pre="infection patients did not have the prodromal symptoms of upper" exact="respiratory" post="tract infection (e.g., cough, sore throat, rhinorrhea), viremia-associated laboratory"/>
 <result pre="did not have the prodromal symptoms of upper respiratory tract" exact="infection" post="(e.g., cough, sore throat, rhinorrhea), viremia-associated laboratory abnormalities (e.g.,"/>
 <result pre="throat, rhinorrhea), viremia-associated laboratory abnormalities (e.g., leukopenia, lymphopenia, anemia, elevation" exact="of liver" post="enzymes and lactic dehydrogenase), or initial evidence of diagnostic"/>
 <result pre="liver enzymes and lactic dehydrogenase), or initial evidence of diagnostic" exact="chest" post="roentgenographic abnormalities.6,11 In addition, uncertain seasonality and the incubation"/>
 <result pre="In addition, uncertain seasonality and the incubation period of SARS-CoV-2" exact="infection" post="oscillating between 2 and 14 days make it remarkably"/>
 <result pre="children are considered to be significantly less susceptible to HCoV-NL63" exact="infection" post="and have milder disease severity than adults,1,5,8,13 the SARS-CoV-2"/>
 <result pre="be significantly less susceptible to HCoV-NL63 infection and have milder" exact="disease" post="severity than adults,1,5,8,13 the SARS-CoV-2 infection has become a"/>
 <result pre="infection and have milder disease severity than adults,1,5,8,13 the SARS-CoV-2" exact="infection" post="has become a public health menace to people around"/>
 <result pre="world presently because of high transmission potential and unpredictability of" exact="disease" post="progression.14 In order to contain SARS-CoV-2 spread among community"/>
 <result pre="In order to contain SARS-CoV-2 spread among community residents, stringent" exact="infection" post="control measures were implemented by the Centers for Disease"/>
 <result pre="stringent infection control measures were implemented by the Centers for" exact="Disease" post="Control (CDC) and Prevention of Taiwan since February, 2020."/>
 <result pre="an investigation by To et al. (2020),15 patients with SARS-CoV" exact="infection" post="had the highest viral load (measured from posterior oropharyngeal"/>
 <result pre="et al. (2020),15 patients with SARS-CoV infection had the highest" exact="viral" post="load (measured from posterior oropharyngeal saliva samples) close to"/>
 <result pre="with SARS-CoV infection had the highest viral load (measured from" exact="posterior" post="oropharyngeal saliva samples) close to when they presented. To"/>
 <result pre="to when they presented. To et al. concluded that since" exact="viral" post="load had already peaked around the time of hospital"/>
 <result pre="most promising and hopeful anti-viral therapeutic. It works by targeting" exact="viral" post="RNA-dependent RNA polymerase (RdRp) while evading proofreading by viral"/>
 <result pre="targeting viral RNA-dependent RNA polymerase (RdRp) while evading proofreading by" exact="viral" post="exoribonuclease,17 resulting in premature termination of viral RNA transcription."/>
 <result pre="evading proofreading by viral exoribonuclease,17 resulting in premature termination of" exact="viral" post="RNA transcription. Unlike other nucleotide analogues, remdesivir is a"/>
 <result pre="Pneumoviridae, and Orthocoronavirinae (such as pathogenic SARS-CoV and Middle East" exact="respiratory" post="syndrome coronavirus [MERS-CoV]).18,19 Information regarding the pharmacokinetics of remdesivir"/>
 <result pre="and Orthocoronavirinae (such as pathogenic SARS-CoV and Middle East respiratory" exact="syndrome" post="coronavirus [MERS-CoV]).18,19 Information regarding the pharmacokinetics of remdesivir in"/>
 <result pre="high intracellular concentration (&amp;gt;10 μM) of active triphosphate form in" exact="peripheral" post="blood mononuclear cells for at least 24 h,20 supporting"/>
 <result pre="USA was successfully treated with remdesivir for the progression of" exact="pneumonia" post="on day 7 of hospitalization in January, 2020.4 Phase"/>
 <result pre="trials (ClinicalTrials.gov Identifier: NCT04292899 and NCT04292730, for severe and moderate" exact="adult" post="SARS-CoV-2 cases, respectively) have been initiated to evaluate its"/>
 <result pre="been initiated to evaluate its efficacy in patients with SARS-CoV-2" exact="infection" post="since March, 2020. Patients received 200 mg on day"/>
 <result pre="of remdesivir were shown to produce a significant reduction in" exact="pulmonary" post="viral load (i.e., &amp;gt;2 orders of magnitude on day"/>
 <result pre="remdesivir were shown to produce a significant reduction in pulmonary" exact="viral" post="load (i.e., &amp;gt;2 orders of magnitude on day 2–5"/>
 <result pre="(i.e., &amp;gt;2 orders of magnitude on day 2–5 post-infection), mitigate" exact="disease" post="progression and prominently improve respiration function.18 Furthermore, Brown et"/>
 <result pre="phosphoribosylated form, favipiravir is easily recognized as a substrate of" exact="viral" post="RNA polymerase in many RNA viruses.27 The recommended dose"/>
 <result pre="in China in March, 2020. In addition, patients with COVID-19" exact="infection" post="are being recruited for randomized trials to evaluate the"/>
 <result pre="analogue antiviral drug that has been used to treat several" exact="viral" post="infections, including hepatitis C virus, respiratory syncytial virus (RSV),"/>
 <result pre="that has been used to treat several viral infections, including" exact="hepatitis" post="C virus, respiratory syncytial virus (RSV), and some viral"/>
 <result pre="used to treat several viral infections, including hepatitis C virus," exact="respiratory" post="syncytial virus (RSV), and some viral hemorrhagic fevers. The"/>
 <result pre="including hepatitis C virus, respiratory syncytial virus (RSV), and some" exact="viral" post="hemorrhagic fevers. The in vitro antiviral activity of ribavirin"/>
 <result pre="effect of reducing hemoglobin, which is harmful for patients in" exact="respiratory" post="distress.19 Interferons Treatment with interferon β (IFNb)-1b (Bayer Pharmaceutical"/>
 <result pre="are important agents in the contemporary treatment of patients with" exact="chronic" post="human immunodeficiency virus (HIV) infection. In the Orthocoronavirinae family,"/>
 <result pre="agents in the contemporary treatment of patients with chronic human" exact="immunodeficiency" post="virus (HIV) infection. In the Orthocoronavirinae family, the targets"/>
 <result pre="culture model is controversial, despite a good effect in mitigating" exact="disease" post="progression in MERS-CoV-infected marmosets.29 Of note, Sheahan et al."/>
 <result pre="LPV's half-life)-IFNb combination therapy in a humanized transgenic mouse MERS-CoV" exact="infection" post="model. They observed the efficacy of remdesivir was superior"/>
 <result pre="superior to that of LPV/RTV-IFNb against MERS-CoV in terms of" exact="viral" post="load reduction and improvement in extent of pathologic change"/>
 <result pre="0.09) and there was no difference in the reduction of" exact="viral" post="RNA loading for severe SARS-CoV-2 patients.32 Despite discouraging results,"/>
 <result pre="patients.32 Despite discouraging results, it is intriguing that a slightly" exact="lower" post="number of deaths was observed in the group receiving"/>
 <result pre="the group receiving LPV/RTV in the late stage of SARS-CoV-2" exact="infection" post="compared with the standard-care group. Moreover, Baden and Ruben"/>
 <result pre="al. (2020) suggested that the LPV/RTV concentration necessary to inhibit" exact="pulmonary" post="SARS-CoV-2 replication might be higher than the serum level.31,33"/>
 <result pre="(200/50 mg twice a day) among hospitalized patients with SARS-CoV-2" exact="infections" post="in 2020 (ChiCTR2000029308). The role of darunavir (Janssen Pharmaceutica,"/>
 <result pre="tissue culture.36 Chloroquine, hydroxychloroquine, and azithromycin Chloroquine is active against" exact="malaria" post="as well as autoimmune diseases (such as rheumatoid arthritis"/>
 <result pre="and azithromycin Chloroquine is active against malaria as well as" exact="autoimmune" post="diseases (such as rheumatoid arthritis [RA], lupus erythematosus). It"/>
 <result pre="active against malaria as well as autoimmune diseases (such as" exact="rheumatoid arthritis" post="[RA], lupus erythematosus). It was recently reported as a"/>
 <result pre="against malaria as well as autoimmune diseases (such as rheumatoid" exact="arthritis" post="[RA], lupus erythematosus). It was recently reported as a"/>
 <result pre="as well as autoimmune diseases (such as rheumatoid arthritis [RA]," exact="lupus" post="erythematosus). It was recently reported as a potential broad-spectrum"/>
 <result pre="vitro (EC50 values: 0.72 and 5.47 μM, respectively) and has" exact="lower" post="potential for drug–drug interactions than chloroquine. Pharmacokinetic models demonstrate"/>
 <result pre="agent on 26 March, 2020. Of note, patients with retinopathy," exact="deficiency" post="of glucose-6-phosphatase, QTc prolongation in electrocardiograms, history of allergy"/>
 <result pre="retinopathy, deficiency of glucose-6-phosphatase, QTc prolongation in electrocardiograms, history of" exact="allergy" post="to hydroxychloroquine or who are pregnant or breastfeeding are"/>
 <result pre="azithromycin is thought to have good potential in preventing severe" exact="respiratory" post="tract infections among pre-school children when it is administrated"/>
 <result pre="thought to have good potential in preventing severe respiratory tract" exact="infections" post="among pre-school children when it is administrated to patients"/>
 <result pre="among pre-school children when it is administrated to patients suffering" exact="viral" post="infection.44 According to one recent study, azithromycin (500 mg"/>
 <result pre="alternative to remdesivir in the treatment of patients with SARS-CoV-2" exact="infection" post="in the future. Nevertheless, the possibility of complicated QTc"/>
 <result pre="L and cathepsin B, which are responsible for cleaving the" exact="viral" post="glycoprotein allowing exposure of the receptor-binding domain of its"/>
 <result pre="to greatly enhance the anti-SARS-CoV-2 activity of hydroxychloroquine) Inhibition of" exact="viral" post="exocytosis Interferon-α 2aInterferon-β 1b Inhibition of papain-like protease and"/>
 <result pre="as prophylactic and therapeutic tools (targeting hemagglutinin binding) against some" exact="viral" post="infections, such as influenza.48 Current efforts in developing monoclonal"/>
 <result pre="with human monoclonal antibodies only provided protection against early stage" exact="disease" post="caused by MERS-CoV in mouse models.19,50 Numerous in vitro"/>
 <result pre="that the spike protein of SARS-CoV is important in mediating" exact="viral" post="entry into target cells. Furthermore, the cleavage and subsequent"/>
 <result pre="a protease of the host cell is absolutely essential for" exact="infectious" post="viral entry.51 Type II transmembrane serine protease TMPRSS2 was"/>
 <result pre="protease of the host cell is absolutely essential for infectious" exact="viral" post="entry.51 Type II transmembrane serine protease TMPRSS2 was suggested"/>
 <result pre="the host cell is absolutely essential for infectious viral entry.51" exact="Type II" post="transmembrane serine protease TMPRSS2 was suggested to be an"/>
 <result pre="resort to improve the survival rate of patients with various" exact="viral" post="infections, such as SARS, H5N1 avian influenza, pandemic 2009"/>
 <result pre="of patients with various viral infections, such as SARS, H5N1" exact="avian influenza," post="pandemic 2009 influenza A H1N1 (H1N1 pdm09), and severe"/>
 <result pre="the immunoglobulin antibodies in the plasma of patients recovering from" exact="viral infection" post="might suppress viremia. Shen et al. (2020) reported on"/>
 <result pre="immunoglobulin antibodies in the plasma of patients recovering from viral" exact="infection" post="might suppress viremia. Shen et al. (2020) reported on"/>
 <result pre="reported on five critically ill patients with laboratory-confirmed COVID-19 and" exact="acute respiratory distress syndrome" post="(ARDS) who received transfusion with convalescent plasma with a"/>
 <result pre="on five critically ill patients with laboratory-confirmed COVID-19 and acute" exact="respiratory" post="distress syndrome (ARDS) who received transfusion with convalescent plasma"/>
 <result pre="critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress" exact="syndrome" post="(ARDS) who received transfusion with convalescent plasma with a"/>
 <result pre="within 3 days (in 4/5 patients), decrease in Sequential Organ" exact="Failure" post="Assessment score, rise in PaO2/FiO2, resolution of ARDS (4"/>
 <result pre="(3 patients within 2 weeks of treatment), and decline in" exact="viral" post="loads (became negative within 12 days) and increase in"/>
 <result pre="stay: 53, 51, and 55 days), while 2 were in" exact="stable condition" post="at 37 days after transfusions.56 The authors concluded that"/>
 <result pre="evidence for these treatments in the prevention of this emerging" exact="viral infection" post="is lacking.57,58 During the COVID-19 outbreak in China, some"/>
 <result pre="for these treatments in the prevention of this emerging viral" exact="infection" post="is lacking.57,58 During the COVID-19 outbreak in China, some"/>
 <result pre="of anti-influenza agents and anti-bacterial agents in patients with COVID-19" exact="pneumonia" post="was common.59 Consequently, a cautious prescription of effective antibiotic(s)"/>
 <result pre="Streptococcus pneumoniae, Klebsiella pneumoniae, and Pseudomonas aeruginosa as well as" exact="Acinetobacter" post="baumannii species for patients undergoing long hospitalization (&amp;gt;6 days)"/>
 <result pre="among the non-survivors of COVID-19 in intensive care units were" exact="cerebrovascular disease" post="and diabetes. Similar findings were also observed by Guan"/>
 <result pre="the non-survivors of COVID-19 in intensive care units were cerebrovascular" exact="disease" post="and diabetes. Similar findings were also observed by Guan"/>
 <result pre="patients were usually treated with ACE inhibitors or angiotensin II" exact="type I" post="receptor blockers (ARB). As mentioned above,5,12 SARS-CoV-2 and SARS-CoV"/>
 <result pre="to their target cells through ACE2 receptors expressed by the" exact="epithelial" post="cells of lung, intestine and kidney.64 Consequently, careful administration"/>
 <result pre="of an ACE inhibitor or ARB for patients with SARS-CoV" exact="infection" post="in the absence of ARDS is advised. Additionally, despite"/>
 <result pre="inhibitor or ARB for patients with SARS-CoV infection in the" exact="absence of" post="ARDS is advised. Additionally, despite conflicting advice from the"/>
 <result pre="severe COVID-19 patients. The 28-day mortality of heparin users was" exact="lower" post="than that of non-users among patients with sepsis-induced coagulopathy"/>
 <result pre="was lower than that of non-users among patients with sepsis-induced" exact="coagulopathy" post="scores ≥4 (40.0% vs. 64.2%, P = 0.029), or"/>
 <result pre="vs. 64.2%, P = 0.029), or D-dimer &amp;gt; 6-fold the" exact="upper" post="limit of normal (32.8% vs. 52.4%, P = 0.017).69"/>
 <result pre="is associated with reduced severity of ARDS among patients with" exact="lower" post="respiratory tract infection caused by RSV.70 Fedson et al."/>
 <result pre="associated with reduced severity of ARDS among patients with lower" exact="respiratory" post="tract infection caused by RSV.70 Fedson et al. (2016,"/>
 <result pre="reduced severity of ARDS among patients with lower respiratory tract" exact="infection" post="caused by RSV.70 Fedson et al. (2016, 2020) observed"/>
 <result pre="(2016, 2020) observed that statins target the host response to" exact="infection" post="(endothelial dysfunction) rather than the virus itself, and suggested"/>
 <result pre="treatment of refractory shock in patients with COVID-19. Funding No" exact="external" post="funding. Declaration of Competing Interest The authors declare that"/>
 <result pre="References References 1ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="ahead of print] 3WuZ.McGooganJ.M.Characteristics of and important lessons from the" exact="coronavirus disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="of print] 3WuZ.McGooganJ.M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="a report of 72314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA2020 Feb 2410.1001/jama.2020.2648[Epub ahead of print] 4HolshueM.L.DeBoltC.LindquistS.LofyK.H.WiesmanJ.BruceH.First"/>
 <result pre="Infect2020 Feb 2510.1016/j.jmii.2020.02.011pii: S1684-1182(20)30039-6. [Epub ahead of print] 6HuangW.H.TengL.C.YehT.K.ChenY.J.LoW.J.WuM.J.2019 Novel" exact="coronavirus disease" post="(COVID-19) in Taiwan: reports of two cases from Wuhan,"/>
 <result pre="Feb 2510.1016/j.jmii.2020.02.011pii: S1684-1182(20)30039-6. [Epub ahead of print] 6HuangW.H.TengL.C.YehT.K.ChenY.J.LoW.J.WuM.J.2019 Novel coronavirus" exact="disease" post="(COVID-19) in Taiwan: reports of two cases from Wuhan,"/>
 <result pre="patients with 2019 novel coronavirus in the early stagemedRxiv202010.1101/2020.02.10.20021584 9CaoQ.ChenY.C.ChenC.L.ChiuC.H.SARS-CoV-2" exact="infection" post="in children: transmission dynamics and clinical characteristicsJ Formos Med"/>
 <result pre="dynamics and clinical characteristicsJ Formos Med Assoc119202067067332139299 10PeirisJ.S.ChuC.M.ChengV.C.ChanK.S.HungI.F.PoonL.L.Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
 <result pre="11ChenN.ZhouM.DongX.QuJ.GongF.HanY.Epidemiological and clinical characteristics of 99 cases of 2019 novel" exact="coronavirus pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751332007143 12HofmannH.PyrcK.van der HoekL.GeierM.BerkhoutB.PöhlmannS.Human"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751332007143 12HofmannH.PyrcK.van der HoekL.GeierM.BerkhoutB.PöhlmannS.Human"/>
 <result pre="descriptive studyLancet395202050751332007143 12HofmannH.PyrcK.van der HoekL.GeierM.BerkhoutB.PöhlmannS.Human coronavirus NL63 employs the severe" exact="acute" post="respiratory syndrome coronavirus receptor for cellular entryProc Natl Acad"/>
 <result pre="studyLancet395202050751332007143 12HofmannH.PyrcK.van der HoekL.GeierM.BerkhoutB.PöhlmannS.Human coronavirus NL63 employs the severe acute" exact="respiratory" post="syndrome coronavirus receptor for cellular entryProc Natl Acad Sci"/>
 <result pre="12HofmannH.PyrcK.van der HoekL.GeierM.BerkhoutB.PöhlmannS.Human coronavirus NL63 employs the severe acute respiratory" exact="syndrome" post="coronavirus receptor for cellular entryProc Natl Acad Sci USA10220057988799315897467"/>
 <result pre="for cellular entryProc Natl Acad Sci USA10220057988799315897467 13LeeK.H.YooS.G.ChoY.KwonD.E.LaY.HanS.H.Characteristics of community-acquired" exact="respiratory" post="viruses infections except seasonal influenza in transplant recipients and"/>
 <result pre="entryProc Natl Acad Sci USA10220057988799315897467 13LeeK.H.YooS.G.ChoY.KwonD.E.LaY.HanS.H.Characteristics of community-acquired respiratory viruses" exact="infections" post="except seasonal influenza in transplant recipients and non-transplant critically"/>
 <result pre="and MERS to 2019-nCoVJ Microbiol Immunol Infect53202036536710.1016/j.jmii.2020.02.001 15ToK.W.TsangT.Y.LeungW.S.TamA.R.WuT.C.LungD.C.Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
 <result pre="2019-nCoVJ Microbiol Immunol Infect53202036536710.1016/j.jmii.2020.02.001 15ToK.W.TsangT.Y.LeungW.S.TamA.R.WuT.C.LungD.C.Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort studyLancet Infect Dis2020 Mar"/>
 <result pre="for the 2019 novel coronavirus (2019-nCoV)Nat Rev Drug Discov19202014915010.1038/d41573-020-00016-032127666 17AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) Is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) Is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBio9201810.1128/mBio.00221-18pii: e00221-18 18SheahanT.P.SimsA.C.GrahamR.L.MenacheryV.D.GralinskiL.E.CaseJ.B.Broad-spectrum antiviral GS-5734"/>
 <result pre="coronavirusesSci Transl Med9201710.1126/scitranslmed.aal3653pii: eaal3653 19MartinezM.A.Compounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirusAntimicrob Agents Chemother2020 Mar 910.1128/AAC.00399-20pii: AAC.00399-20 20WarrenT.K.JordanR.LoM.K.RayA.S.MackmanR.L.SolovevaV.Therapeutic efficacy"/>
 <result pre="rhesus monkeysNature531201638138526934220 21MulanguS.DoddL.E.DaveyR.T.Jr.Tshiani MbayaO.ProschanM.MukadiD.A randomized, controlled trial of Ebola virus" exact="disease" post="therapeuticsN Engl J Med38120192293230331774950 22Medrxiv Newsfromhttps://times.hinet.net/mobile/news/22831665 23BrownA.J.WonJ.J.GrahamR.L.DinnonK.H.3rdSimsA.C.FengJ.Y.Broad spectrum antiviral"/>
 <result pre="Dec 1110.1093/infdis/jiz656pii: jiz656 27FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Jpn Acad Ser B Phys Biol Sci932017449463"/>
 <result pre="Fromhttp://www.xinhuanet.com/english/2020-03/17/c_138888226.htm 29ChanJ.F.W.YaoY.YeungM.L.DengW.BaoL.JiaL.Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
 <result pre="clinical findingsThorax59200425225614985565 37YanY.ZouZ.SunY.LiX.XuK.F.WeiY.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal modelCell Res23201330030223208422"/>
 <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal modelCell Res23201330030223208422 38VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res23201330030223208422 38VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent"/>
 <result pre="animal modelCell Res23201330030223208422 38VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS" exact="coronavirus infection" post="and spreadVirol J220056910.1186/1743-422X-2-6916115318 39WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and chloroquine effectively inhibit the"/>
 <result pre="modelCell Res23201330030223208422 38VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J220056910.1186/1743-422X-2-6916115318 39WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and chloroquine effectively inhibit the"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii:"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: S1684-1182"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: S1684-1182 42GautretP.LagierJ.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine"/>
 <result pre="Infect Dis1201531732627622822 44BacharierL.B.GuilbertT.W.MaugerD.T.BoehmerS.BeigelmanA.FitzpatrickA.M.Early administration of azithromycin and prevention of severe" exact="lower" post="respiratory tract illnesses in preschool children with a history"/>
 <result pre="Dis1201531732627622822 44BacharierL.B.GuilbertT.W.MaugerD.T.BoehmerS.BeigelmanA.FitzpatrickA.M.Early administration of azithromycin and prevention of severe lower" exact="respiratory" post="tract illnesses in preschool children with a history of"/>
 <result pre="such illnesses: a randomized clinical trialJAMA31420152034204426575060 45WangY.CuiR.LiG.GaoQ.YuanS.AltmeyerR.Teicoplanin inhibits Ebola pseudovirus" exact="infection" post="in cell cultureAntivir Res12520161710.1016/j.antiviral.2015.11.00326585243 46ZhouN.PanT.ZhangJ.LiQ.ZhangX.BaiC.Glycopeptide antibiotics potently inhibit cathepsin"/>
 <result pre="endosome/lysosome and block the entry of Ebola virus, Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome coronavirus"/>
 <result pre="and block the entry of Ebola virus, Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV)J"/>
 <result pre="of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and" exact="Severe" post="Acute Respiratory Syndrome coronavirus (SARS-CoV)J Biol Chem29120169218923226953343 47BaronS.A.DevauxC.ColsonP.RaoultD.RolainJ.M.Teicoplanin: an"/>
 <result pre="Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and Severe" exact="Acute" post="Respiratory Syndrome coronavirus (SARS-CoV)J Biol Chem29120169218923226953343 47BaronS.A.DevauxC.ColsonP.RaoultD.RolainJ.M.Teicoplanin: an alternative"/>
 <result pre="virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and Severe Acute" exact="Respiratory" post="Syndrome coronavirus (SARS-CoV)J Biol Chem29120169218923226953343 47BaronS.A.DevauxC.ColsonP.RaoultD.RolainJ.M.Teicoplanin: an alternative drug"/>
 <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV), and Severe Acute Respiratory" exact="Syndrome" post="coronavirus (SARS-CoV)J Biol Chem29120169218923226953343 47BaronS.A.DevauxC.ColsonP.RaoultD.RolainJ.M.Teicoplanin: an alternative drug for"/>
 <result pre="of coronavirus COVID-19?Int J Antimicrob Agents2020 Mar 1310594410.1016/j.ijantimicag.2020.10594432179150 48BeigelJ.H.NamH.H.AdamsP.L.KrafftA.InceW.L.El-KamaryS.S.Advances in" exact="respiratory" post="virus therapeutics - a meeting report from the 6th"/>
 <result pre="single-dose-escalation studyLancet Infect Dis18201841041829329957 50CockrellA.S.YountB.L.ScobeyT.JensenK.DouglasM.BeallA.A mouse model for MERS coronavirus-induced" exact="acute" post="respiratory distress syndromeNat Microbiol220161622627892925 51GlowackaI.BertramS.MüllerM.A.AllenP.SoilleuxE.PfefferleS.Evidence that TMPRSS2 activates the"/>
 <result pre="studyLancet Infect Dis18201841041829329957 50CockrellA.S.YountB.L.ScobeyT.JensenK.DouglasM.BeallA.A mouse model for MERS coronavirus-induced acute" exact="respiratory" post="distress syndromeNat Microbiol220161622627892925 51GlowackaI.BertramS.MüllerM.A.AllenP.SoilleuxE.PfefferleS.Evidence that TMPRSS2 activates the severe"/>
 <result pre="respiratory distress syndromeNat Microbiol220161622627892925 51GlowackaI.BertramS.MüllerM.A.AllenP.SoilleuxE.PfefferleS.Evidence that TMPRSS2 activates the severe" exact="acute" post="respiratory syndrome coronavirus spike protein for membrane fusion and"/>
 <result pre="distress syndromeNat Microbiol220161622627892925 51GlowackaI.BertramS.MüllerM.A.AllenP.SoilleuxE.PfefferleS.Evidence that TMPRSS2 activates the severe acute" exact="respiratory" post="syndrome coronavirus spike protein for membrane fusion and reduces"/>
 <result pre="syndromeNat Microbiol220161622627892925 51GlowackaI.BertramS.MüllerM.A.AllenP.SoilleuxE.PfefferleS.Evidence that TMPRSS2 activates the severe acute respiratory" exact="syndrome" post="coronavirus spike protein for membrane fusion and reduces viral"/>
 <result pre="respiratory syndrome coronavirus spike protein for membrane fusion and reduces" exact="viral" post="control by the humoral immune responseJ Virol8520114122413421325420 52KawaseM.ShiratoK.van der"/>
 <result pre="immune responseJ Virol8520114122413421325420 52KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
 <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entryJ Virol8620126537654522496216 53ZhouY.VedanthamP.LuK.AgudeloJ.CarrionR.Jr.NunneleyJ.W.Protease inhibitors targeting coronavirus"/>
 <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entryJ Virol8620126537654522496216 53ZhouY.VedanthamP.LuK.AgudeloJ.CarrionR.Jr.NunneleyJ.W.Protease inhibitors targeting coronavirus and"/>
 <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entryJ Virol8620126537654522496216 53ZhouY.VedanthamP.LuK.AgudeloJ.CarrionR.Jr.NunneleyJ.W.Protease inhibitors targeting coronavirus and filovirus"/>
 <result pre="58LuoH.TangQ.L.ShangY.X.LiangS.B.YangM.RobinsonN.Can Chinese medicine be used for prevention of corona virus" exact="disease" post="2019 (COVID-19)? A review of historical classics, research evidence"/>
 <result pre="with COVID-19.(manuscript submitted). 60ChouC.C.ShenC.F.ChenS.J.ChenH.M.WangY.C.ChangW.S.Recommendations and guidelines for the treatment of" exact="pneumonia" post="in TaiwanJ Microbiol Immunol Infect52201917219910.1016/j.jmii.2018.11.00430612923 61JeanS.S.ChangY.C.LinW.C.LeeW.S.HsuehP.R.HsuC.W.Epidemiology, treatment, and prevention"/>
 <result pre="TaiwanJ Microbiol Immunol Infect52201917219910.1016/j.jmii.2018.11.00430612923 61JeanS.S.ChangY.C.LinW.C.LeeW.S.HsuehP.R.HsuC.W.Epidemiology, treatment, and prevention of nosocomial" exact="bacterial" post="pneumoniaJ Clin Med9202027510.3390/jcm9010275 62YangX.YuY.XuJ.ShuH.XiaJ.LiuH.Clinical course and outcomes of critically"/>
 <result pre="62YangX.YuY.XuJ.ShuH.XiaJ.LiuH.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir"/>
 <result pre="retrospective, observational studyLancet Respir Med2020 Feb 2410.1016/S2213-2600(20)30079-5 63GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.Clinical characteristics of" exact="coronavirus disease" post="2019 in ChinaN Engl J Med2020 Feb 2810.1056/NEJMoa2002032 64FangL.KarakiulakisG.RothM.Are"/>
 <result pre="observational studyLancet Respir Med2020 Feb 2410.1016/S2213-2600(20)30079-5 63GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med2020 Feb 2810.1056/NEJMoa2002032 64FangL.KarakiulakisG.RothM.Are"/>
 <result pre="in ChinaN Engl J Med2020 Feb 2810.1056/NEJMoa2002032 64FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="Engl J Med2020 Feb 2810.1056/NEJMoa2002032 64FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir Med2020 Mar"/>
 <result pre="67Society of Critical Care MedicineCOVID-19 GuidelinesFrom:https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19 68WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.Risk factors associated with" exact="acute respiratory distress syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="of Critical Care MedicineCOVID-19 GuidelinesFrom:https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19 68WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
 <result pre="Care MedicineCOVID-19 GuidelinesFrom:https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19 68WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="with acute respiratory distress syndrome and death in patients with" exact="coronavirus disease" post="2019 pneumonia in Wuhan, ChinaJAMA Intern Med2020 Mar 1310.1001/jamainternmed.2020.0994"/>
 <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, ChinaJAMA Intern Med2020 Mar 1310.1001/jamainternmed.2020.0994"/>
 <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, ChinaJAMA Intern Med2020 Mar 1310.1001/jamainternmed.2020.0994 69TangN.BaiH.ChenX.GongJ.LiD.SunZ.Anticoagulant treatment"/>
 <result pre="1310.1001/jamainternmed.2020.0994 69TangN.BaiH.ChenX.GongJ.LiD.SunZ.Anticoagulant treatment is associated with decreased mortality in severe" exact="coronavirus disease" post="2019 patients with coagulopathyJ Thromb Haemost2020 March 2710.1111/jth.14817 70Wösten-van"/>
 <result pre="69TangN.BaiH.ChenX.GongJ.LiD.SunZ.Anticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathyJ Thromb Haemost2020 March 2710.1111/jth.14817 70Wösten-van"/>
 <result pre="with coagulopathyJ Thromb Haemost2020 March 2710.1111/jth.14817 70Wösten-van AsperenR.M.BosA.P.BemR.A.DierdorpB.S.DekkerT.van GoorH.Imbalance between" exact="pulmonary" post="angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute"/>
 <result pre="between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in" exact="acute" post="respiratory distress syndromePediatr Crit Care Med142013e438e44110.1097/PCC.0b013e3182a5573524226567 71FedsonD.S.Treating the host"/>
 <result pre="pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute" exact="respiratory" post="distress syndromePediatr Crit Care Med142013e438e44110.1097/PCC.0b013e3182a5573524226567 71FedsonD.S.Treating the host response"/>
</results>
